Go to deals
Healthcare

Laboratoire Dazont has been acquired by SBM Company

The shareholders of Laboratoire Dazont have sold the company to SBM Company.

Created in 2008, Laboratoire Dazont is a France-based company specialized in the design, manufacture and distribution of natural veterinary solutions for pharmacies and parapharmacies. The company offers a complete range of approximately 50 references of natural products, including aromatherapy, petcare, and products and food supplements for dogs and cats under the Vetoform and Vetonut brands. Laboratoire Dazont offers its solutions to 750 pharmacies and parapharmacies in France, including key accounts such as E. Leclerc and Santédiscount.

Created in 1994, SBM Company is a family-owned French group with presence in more than 31 countries throughout Europe and North America. SBM designs, homologates, produces and markets products for the care and protection of crops, gardens and homes. In 2021, the group generated approximately US$360 million in sales, 60% internationally.

Oaklins’ team in France acted as M&A advisor to Laboratoire Dazont in the disposal of the company to SBM Company.

Parties

Talk to the deal team

 Ludovic  Beaulieu

Ludovic Beaulieu

Partner
Paris, France
Oaklins France
 Quentin  Boissinot

Quentin Boissinot

Associate
Paris, France
Oaklins France

Related deals

A group of Chilean investors has acquired Farmacias Ahumada
Consumer & Retail | Healthcare

A group of Chilean investors has acquired Farmacias Ahumada

A group of Chilean investors has acquired Farmacias Ahumada S.A. from Walgreens Boots Alliance.

Learn more
Alcidion has raised capital
Healthcare

Alcidion has raised capital

Alcidion Group Ltd. (ASX:ALC) has raised capital via an institutional placement. The placement was well supported by existing shareholders whilst also welcoming several new institutional shareholders to the register. Proceeds from the raise will provide Alcidion with maximum flexibility and ensure a strong balance sheet to execute on its market opportunities and enable the firm to continue to drive revenue growth.

Learn more
Shield Therapeutics has completed a fundraising
Healthcare

Shield Therapeutics has completed a fundraising

Shield Therapeutics plc has raised funds to bolster the expansion of ACCRUFeR®, the sole FDA-approved therapy for iron deficiency and to drive the business. Additionally, it positions the company for further investments.

Learn more